Samuel Goldhaber, MD

Samuel Goldhaber, MD

Program Co-Chair
Section Head, Vascular Medicine
Director, Thrombosis Research Group
Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA USA

Related Videos

Based on the results of ODYSSEY Outcomes and FOURIER, do you recommend that clinicians strive, in selected high-risk populations, to lower LDL-C significantly lower than 70 mg/dL? Video

Based on the results of ODYSSEY Outcomes and FOURIER, do you recommend that clinicians strive, in selected high-risk populations, to lower LDL-C significantly lower than 70 mg/dL?

As a thrombosis specialist and cardiologist, how do respond to the recent AHA guidelines identifying <70 mg/dL as a threshold target for high-risk patients? Is this target a starting point or a stopping point for your LDL-C lowering goals? Video

As a thrombosis specialist and cardiologist, how do respond to the recent AHA guidelines identifying <70 mg/dL as a threshold target for high-risk patients? Is this target a starting point or a stopping point for your LDL-C lowering goals?

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role? Video

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role?

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy? Video

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy?

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents? Video

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?